Response and resistance in immuno-oncology
Related
Updated March 3, 2023
Explore tumor-specific response and resistance to cancer immunotherapies with our highly validated research solutions.
Overview
What is immunotherapy?
Immunotherapy is a revolutionary approach to cancer treatment that helps the immune system recognize and attack cancer cells1. Current immunotherapies include immune checkpoint inhibitors, CAR-T cells, vaccines, and monoclonal antibodies that, for a subset of patients, has provided long-term, durable responses to a variety of cancers. However, some patients fail to respond to treatment at all, while others achieve a limited response followed by tumor progression. Therefore, understanding the factors that contribute to an effective response and determining mechanisms of resistance will be critical as immunotherapies are applied more broadly2.
Flexible, extensively validated research solutions
Discover reagents to novel targets and emerging multiplex technologies to support your immuno-oncology research and assay development. These include recombinant antibodies for highly reproducible results, hand-picked antibody panels to immune checkpoints, and antibodies validated in flow cytometry to empower your research. Here we’ve highlighted products to key targets so you can easily select the best one.
Key targets involved in tumor resistance: STING, IDO1, VISTA, and ARG1
| Target | Product recommendation |
| STING | Recombinant STING (Anti-TMEM173 antibody [EPR13130-55] (ab239074)
Suitable for: WB, ICC/IF, IP, IHC-P, Flow Cyt Reacts with: Human |
| IDO1 | Recombinant IDO1 (anti-Indoleamine 2, 3-dioxygenase) antibody [EPR20374] (ab211017)
Suitable for: WB, ICC/IF, Flow Cyt, IP, IHC-P Reacts with: Human |
| VISTA |
